New York-based Delcath Systems, Inc. is an interventional oncology company that specializes in treating primary and metastatic liver cancers across the United States and Europe. The company's standout offering is its HEPZATO KIT, an injection and hepatic delivery system that utilizes melphalan hydrochloride to provide high-dose chemotherapy to the liver while minimizing associated side effects. Delcath's clinical development program for HEPZATO focuses primarily on the FOCUS trial, which aims to study the objective response rate in patients with hepatic dominant ocular melanoma. The company also provides HEPZATO as a stand-alone medical device and markets it under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT across medical centers across Europe. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.
Delcath Systems's ticker is DCTH
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 11-50 employees working at Delcath Systems
It is delcath.com
Delcath Systems is in the Healthcare sector
Delcath Systems is in the Drug Delivery industry
The following five companies are Delcath Systems's industry peers: